New UGent/VUB spin-off Gulliver Biomed brings llama antibodies to research community

Gulliver Biomed will develop customer-oriented antibodies in llamas that can be used as a tool in fundamental research, but also for evaluation in (pre-) clinical studies as potential candidates for diagnostic or therapeutic applications. These unique antibodies, also known as nanobodies, were discovered at the VUB in the late 1980s by professor Muyldermans. 

Read more.